Growth Metrics

Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2025)

Historic Non-Current Deferred Tax Liability for Halozyme Therapeutics (HALO) over the last 3 years, with Q3 2025 value amounting to $8.2 million.